Published in Am J Dis Child on July 01, 1977
Production and characterization of monoclonal antibodies specific for a glycosylated polypeptide of human cytomegalovirus. J Clin Microbiol (1983) 1.91
Evaluation of a radioimmunoassay for IgM-class antibodies against cytomegalovirus. Br J Exp Pathol (1980) 1.57
Expression of a human cytomegalovirus receptor correlates with infectibility of cells. J Virol (1991) 1.48
Definition of a subset of human peripheral blood mononuclear cells that are permissive to human cytomegalovirus infection. J Virol (1993) 1.48
Improved indirect hemagglutination test for cytomegalovirus using human O erythrocytes in lysine. J Clin Microbiol (1979) 1.47
Inflammatory cells in transplanted kidneys are infected by human cytomegalovirus. Am J Pathol (1988) 1.41
An analysis of cytomegalovirus infection and HLA antigen matching on the outcome of renal transplantation. Ann Surg (1978) 1.15
Cellular immune response to cytomegalovirus infection after renal transplantation. Infect Immun (1978) 1.13
Cytomegalovirus-specific cytotoxicity mediated by non-T lymphocytes from peripheral blood of normal volunteers. Infect Immun (1981) 1.03
Detection of virus-specific IgA antibodies in serum of kidney transplant patients with recurrent cytomegalovirus infection by enzymeimmuno and radioimmunoassay techniques. Clin Exp Immunol (1982) 1.02
Increased IgM and IgM immune complex-like material in the circulation of renal transplant recipients with primary cytomegalovirus infections. Clin Exp Immunol (1982) 0.97
Acquisition of cytomegalovirus infection: an update. Clin Microbiol Rev (1989) 0.91
Herpesviruses. J Clin Pathol (1979) 0.89
Monitoring and managing viral infections in pediatric renal transplant recipients. Pediatr Nephrol (2011) 0.86
Comparison of monoclonal and polyclonal antibody for confirmation of cytomegalovirus isolates by fluorescent staining. J Clin Microbiol (1984) 0.85
Cytomegalovirus infections in renal transplant recipients. Br Med J (Clin Res Ed) (1984) 0.82
Cell-mediated immunity to cytomegalovirus in immunocompromised patients: effect of radiation or chemotherapy. Infect Immun (1979) 0.81
Maintenance of cytomegalovirus (CMV) latency and host immune responses of long term renal allograft survivors. I. Prolonged suppression of in vitro lymphocyte responses against CMV infected fibroblasts related to previous secondary CMV infection. Clin Exp Immunol (1985) 0.80
Renal graft dysfunction during infection with cytomegalovirus: association with IgM lymphocytotoxins and HLA-DR3 and DR7. Br Med J (Clin Res Ed) (1983) 0.79
Cytomegalovirus infection in heart transplant recipients: preliminary results of a controlled trial of intravenous gamma globulin. J Clin Immunol (1982) 0.78
Maintenance of cytomegalovirus (CMV) latency and host immune responses of long term renal allograft survivors. II. Secondary CMV infections associated with impaired in vitro proliferative responses to mitogens, allogeneic lymphocytes and CMV infected cells. Clin Exp Immunol (1985) 0.77
A prospective study of cytomegalovirus and herpes simplex virus disease in renal transplant recipients. J Clin Pathol (1982) 0.77
Relationship between cytomegalovirus and colonization of the oropharynx by gram-negative bacilli following renal transplantation. Epidemiol Infect (1991) 0.77
Cytomegalovirus infection complicating immunosuppressive treatment. Postgrad Med J (1988) 0.75
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med (2005) 17.06
Clinically useful method for the isolation of respiratory syncytial virus. J Infect Dis (1975) 5.00
Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA (1999) 4.71
Generation and maintenance of gradients in taxonomic diversity. Science (1969) 4.33
A prospective study of chronic herpes simplex virus infection and recurrent herpes labialis in humans. J Immunol (1970) 4.12
Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob Agents Chemother (1980) 3.60
Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol (1986) 3.33
Virus isolation from and identification of HTLV-III/LAV-producing cells in brain tissue from a patient with AIDS. JAMA (1986) 2.86
Assessing illness severity: does clinical judgment work? J Chronic Dis (1986) 2.82
The Kaposi sarcoma-associated herpesvirus (KSHV) is present as an intact latent genome in KS tissue but replicates in the peripheral blood mononuclear cells of KS patients. J Exp Med (1996) 2.67
Assessment of experimental and natural viral aerosols. Bacteriol Rev (1966) 2.64
Successful treatment of naturally occurring influenza A/USSR/77 H1N1. JAMA (1981) 2.50
New vaccine technologies. JAMA (1994) 2.45
Respiratory syncytial virus infections in infants: quantitation and duration of shedding. J Pediatr (1976) 2.45
Evaluation of influenza A/Hong Kong/123/77 (H1N1) ts-1A2 and cold-adapted recombinant viruses in seronegative adult volunteers. Infect Immun (1980) 2.42
Effect of route of inoculation on experimental respiratory viral disease in volunteers and evidence for airborne transmission. Bacteriol Rev (1966) 2.41
Anomalous ABO phenotype in a child after an ABO-incompatible liver transplantation. N Engl J Med (1992) 2.36
Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines. J Virol (1988) 2.35
Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA (1996) 2.30
Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med (1999) 2.27
Morbidity during hospitalization: can we predict it? J Chronic Dis (1987) 2.21
Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings. J Am Geriatr Soc (1992) 2.17
Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J Infect Dis (1995) 2.13
Correlated studies of a recombinant influenza-virus vaccine. 3. Protection against experimental influenza in man. J Infect Dis (1971) 2.13
Temperature-sensitive mutants of influenza A virus. XII. Safety, antigenicity, transmissibility, and efficacy of influenza A/Udorn/72-ts-1[E] recombinant viruses in human adults. J Infect Dis (1976) 2.12
The role of nasal secretion and serum antibody in the rhinovirus common cold. Am J Epidemiol (1966) 2.11
Interferon production in children with respiratory syncytial, influenza, and parainfluenza virus infections. J Pediatr (1978) 2.01
The milk alkali syndrome: a study of the acute disorder with comments on the development of the chronic condition. Medicine (Baltimore) (1965) 1.97
Viral shedding patterns of children with influenza B infection. J Infect Dis (1979) 1.91
Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection. Lancet (1984) 1.88
Possible transmission by fomites of respiratory syncytial virus. J Infect Dis (1980) 1.87
Nosocomial respiratory syncytial virus infections. N Engl J Med (1975) 1.85
Modes of transmission of respiratory syncytial virus. J Pediatr (1981) 1.84
Neonatal respiratory syncytial virus infection. N Engl J Med (1979) 1.82
Double-blind evaluation of oral ribavirin (Virazole) in experimental influenza A virus infection in volunteers. Antimicrob Agents Chemother (1977) 1.70
Comparative activity of immunofluorescent antibody and complement-fixing antibody in cytomegalovirus infection. J Clin Microbiol (1976) 1.64
Airway hyperreactivity and peripheral airway dysfunction in influenza A infection. Am Rev Respir Dis (1978) 1.62
Rhinovirus neutralizing antibody in tears, parotid saliva, nasal secretions and serum. J Immunol (1967) 1.59
Cytomegalovirus infection in transplant patients. Prog Med Virol (1982) 1.57
How much do immigration and trade affect labor market outcomes? Brookings Pap Econ Act (1997) 1.52
Evaluation of live avian-human reassortant influenza A H3N2 and H1N1 virus vaccines in seronegative adult volunteers. J Clin Microbiol (1986) 1.52
Amantadine effect on peripheral airways abnormalities in influenza. A study in 15 students with natural influenza A infection. Ann Intern Med (1976) 1.52
Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother (2000) 1.50
Infectivity of respiratory syncytial virus by various routes of inoculation. Infect Immun (1981) 1.50
Five-year surveillance of aminoglycoside usage in a university hospital. Ann Intern Med (1984) 1.50
Changes in IgA and IgG concentrations in nasal secretions prior to the appearance of antibody during viral respiratory infection in man. J Immunol (1970) 1.49
Two randomized controlled trials of zinc gluconate lozenge therapy of experimentally induced rhinovirus colds. Antimicrob Agents Chemother (1987) 1.49
An extracorporeal complexing hemodialysis system for the treatment of methylmercury poisoning. I. In vitro studies of the effects of four complexing agents on the distribution and dialyzability of methylmercury in human blood. J Pharmacol Exp Ther (1975) 1.48
Detection of influenza A and B in respiratory secretions with the polymerase chain reaction. PCR Methods Appl (1992) 1.47
Nosocomial influenza infection as a cause of intercurrent fevers in infants. Pediatrics (1975) 1.46
Comparison of live, attenuated H1N1 and H3N2 cold-adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults. J Infect Dis (1988) 1.43
Transesophageal echocardiography reveals an unusual cause of hemodynamic collapse during orthotopic liver transplantation--two case reports. Transplantation (1995) 1.42
Virus-induced interferon production by human macrophages. J Immunol (1979) 1.42
Utility is not just posttransplant outcome! Am J Transplant (2006) 1.40
Amantadine therapy of epidemic influenza a(2) (Hong Kong). Infect Immun (1970) 1.39
Temperature-sensitive mutants of influenza A virus: evaluation of the Alaska/77-ts-1A2 temperature-sensitive recombinant virus in seronegative adult volunteers. Arch Virol (1980) 1.39
Dose response of influenza A/Washington/897/80 (H3N2) cold-adapted reassortant virus in adult volunteers. J Infect Dis (1984) 1.37
Pathogenesis of rhinovirus common colds in human voluteers. Ann Otol Rhinol Laryngol (1970) 1.37
Respiratory syncytial virus and influenza. Practical community surveillance. Am J Dis Child (1976) 1.36
Erythrocyte adenosine triphosphate depletion during hypophosphatemia in a uremic subject. N Engl J Med (1969) 1.35
Relation of chronic disease and immune response to influenza vaccine in the elderly. Vaccine (1989) 1.35
Attenuated influenza produced by experimental intranasal inoculation. J Med Virol (1979) 1.33
Clinical assessments as predictors of one year survival after hospitalization: implications for prognostic stratification. J Clin Epidemiol (1988) 1.32
Responses of elderly subjects to monovalent A/USSR/77 (H1N1) and Trivalent A/USSR/77 (H1N1)-A/TEXAS/77 (H3N2)-B/Hong Kong/72 vaccines. Am Rev Respir Dis (1981) 1.31
Temperature-sensitive mutants of influenza A virus: evaluation of A/Victoria/3/75-ts-1[E] recombinant viruses in volunteers. Infect Immun (1978) 1.30
Fetal cells participate over time in the response to specific types of murine maternal hepatic injury. Hum Reprod (2006) 1.30
Multicenter seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation. Transplantation (1985) 1.29
Effects of ribavirin on respiratory syncytial virus in vitro. Antimicrob Agents Chemother (1980) 1.28
Quantitative shedding patterns of respiratory syncytial virus in infants. J Infect Dis (1975) 1.28
Airborne transmission of respiratory infection with coxsackievirus A type 21. Am J Epidemiol (1970) 1.28
Long-term therapy for chronic bacteriuria in men. U.S. Public Health Service cooperative study. Ann Intern Med (1975) 1.28
Enhancement of activity against influenza viruses by combinations of antiviral agents. Antimicrob Agents Chemother (1980) 1.28
Interferon and resistance to upper respiratory virus illness. Proc Soc Exp Biol Med (1969) 1.27
Airway reactivity in subjects with viral upper respiratory tract infections: the effects of exercise and cold air. Am Rev Respir Dis (1980) 1.27
Evaluation of A/Alaska/6/77 (H3N2) cold-adapted recombinant viruses derived from A/Ann Arbor/6/60 cold-adapted donor virus in adult seronegative volunteers. Infect Immun (1981) 1.27
Quantitative rhinovirus shedding patterns in volunteers. Am Rev Respir Dis (1966) 1.27
Significance of Herpesvirus hominis in respiratory secretions of man. N Engl J Med (1968) 1.26
Cytomegalovirus (CMV) in the compromised host(s). Annu Rev Med (1977) 1.24
A regional end-stage renal disease program: twelve years' experience. Ann Intern Med (1980) 1.23
Malignant external otitis: a severe form of otitis in diabetic patients. Am J Med (1976) 1.23
Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine. J Clin Microbiol (1986) 1.22
Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann Intern Med (1992) 1.21
Cytolytic IgM antibody to cytomegalovirus in primary cytomegalovirus infection in humans. J Infect Dis (1981) 1.20
Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. J Infect Dis (1996) 1.19
Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J Infect Dis (1996) 1.19
Ribavirin treatment of experimental respiratory syncytial viral infection. A controlled double-blind study in young adults. JAMA (1983) 1.18
The use of eye-nose goggles to control nosocomial respiratory syncytial virus infection. JAMA (1986) 1.16